secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001654954-22-011401
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q2 2022 revenue $4.2M, up 51% pro-forma; net loss $5.3M, cash $186.8M
------------------------------------------------------------------------------

- Revenue $4.2M (71% gross margin), up 51% pro-forma vs combined $2.8M in Q2 2021.
- PulseVet revenue $4.2M (+48% standalone); small animal systems sold 22 (20x increase).
- Net loss $5.3M ($0.005/sh) vs $4.7M loss in Q2 2021; 6-month loss $9.2M ($0.009/sh).
- Cash $186.8M; used $5.5M in quarter including $1M convertible note in SMP (VetGuardian).
- Post-quarter acquisitions: Revo 2 imaging assets and Assisi LOOP/Calmer Canine products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422011401/0001654954-22-011401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495422011401/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-011401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer